It’s called ibrutinib, and it’s a potential breakthrough in treating chronic lymphocytic leukemia (CLL) that could leave patients with fewer side effects than chemotherapy. Times Healthland, 06/20/2013. (Also see: Leukemia)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.